NTRK1 and head and neck squamous cell carcinoma: Interestingly, downregulation of the receptor tyrosine kinase AXL has been suggested to enhance the response of HNSCC cells (584 and 1386-LN), as well as breast and lung cancer cells, to olaparib and which was linked with reduced levels of RAD51 foci and decreased HR efficiency (29).